Camobucol (AGIX 4207) is an orally active phenolic antioxidant and anti-inflammatory agent used in the research of rheumatic diseases; it exhibits potent antioxidant activity against lipid peroxides in vitro and shows enhanced cellular uptake; it selectively inhibits TNF-α-inducible expression of redox-sensitive genes such as vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-1), with lesser inhibition of E-selectin and no effect on intercellular adhesion molecule-1 (ICAM-1) in endothelial cells; additionally, it suppresses cytokine-induced production of MCP-1, interleukin (IL)-6, and IL-8 from endothelial cells and human fibroblast-like synoviocytes, as well as lipopolysaccharide-induced release of TNF-α, IL-1β, and IL-6 from human peripheral blood mononuclear cells.